Solid Biosciences Inc. stock analysis

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycar

Ticker: SLDB
Exchange: Nasdaq
Sector: Health Care
Industry: Biotechnology

Market evidence and data freshness

The public preview recorded Solid Biosciences Inc. at 7.28 USD on 2026-09-28T16:55:40.000Z and marked the quote as delayed. This observation is not a trading signal.

Available price history spans 2021-09-30 through 2026-09-04 across 1238 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

What should I review before buying Solid Biosciences Inc. stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

Inside the full analysis

Valuation
Growth
Financial health
Ownership
Research

Sign in to open the full analysis. Paid plans use included reports first, then 50 credits per additional report. Reports outside your included market also cost 50 credits. Credit access lasts 72 hours, including revisits.